Foundry Partners LLC Has $18.97 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Foundry Partners LLC decreased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 5.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 748,723 shares of the biopharmaceutical company's stock after selling 42,665 shares during the quarter. Foundry Partners LLC's holdings in Pfizer were worth $18,973,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Bessemer Group Inc. lifted its position in shares of Pfizer by 11.1% in the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock valued at $3,358,000 after buying an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK boosted its holdings in shares of Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after acquiring an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp acquired a new position in Pfizer during the 1st quarter worth about $8,283,000. Alta Advisers Ltd lifted its holdings in Pfizer by 69.6% during the 1st quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock worth $809,000 after buying an additional 13,100 shares during the period. Finally, WCM Investment Management LLC lifted its holdings in Pfizer by 8.7% during the 1st quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock worth $3,176,000 after buying an additional 10,051 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Trading Down 0.5%

PFE traded down $0.12 during midday trading on Friday, reaching $24.46. 36,271,002 shares of the company were exchanged, compared to its average volume of 41,959,930. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The stock has a market capitalization of $139.06 billion, a P/E ratio of 17.72, a PEG ratio of 0.89 and a beta of 0.58. The stock's 50-day simple moving average is $24.07 and its 200 day simple moving average is $24.73.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the firm posted $0.82 earnings per share. Pfizer's revenue was down 7.8% compared to the same quarter last year. As a group, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.03%. Pfizer's dividend payout ratio is 124.64%.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of recent research reports. HSBC decreased their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. UBS Group increased their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Bank of America increased their target price on Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. TD Cowen dropped their target price on Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research report on Tuesday, April 22nd. Finally, The Goldman Sachs Group upped their price target on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.